SCHEMBL304275

SCHEMBL304275

Cc1cc2c(cc1Br)NCCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
GAA P10253 2/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPT P10636 1/20 0.54
KDM4E B2RXH2 1/20 0.50
GLA P06280 1/20 0.50
HPGD P15428 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
PDE3B Q13370 2/20 0.38
PDE3A Q14432 2/20 0.38
AR P10275 1/20 0.38
TP53 P04637 1/20 0.36
BCHE P06276 1/20 0.35
CES1 P23141 1/20 0.35
BRD4 O60885 1/20 0.35
TRPV1 Q8NER1 2/20 0.33
PRKCI P41743 1/20 0.33
FABP6 P51161 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1853383 0.93 ALDH1A1 (0.54) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL11342856 0.85 ALDH1A1 (0.61) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL31451604 0.83 ALDH1A1 (0.44) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL31451292 0.83 ALDH1A1 (0.44) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL24286432 0.79 ALDH1A1 (0.46) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL9799216 0.79 ALDH1A1 (0.54) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL4125499 0.79 ALDH1A1 (0.46) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL9617547 0.79 ALDH1A1 (0.54) ALDH1A1GAAHSD17B10MAPTKDM4E
SCHEMBL21603157 0.79 ALDH1A1 (0.54) ALDH1A1GAAHSD17B10MAPTKDM4E
Hydrochloric Acid SCHEMBL29221775 0.77 ALDH1A1 (0.45) ALDH1A1GAAHSD17B10MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000490-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2018-06-19 US disclosed
US-10000490-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2018-06-19 US disclosed
US-20170253593-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-09-07 US disclosed
US-20170253593-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-09-07 US disclosed
US-9695165-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2017-07-04 US disclosed
US-9695165-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2017-07-04 US disclosed
WO-2015108992-A1 HETEROBICYCLIC COMPOUNDS AND THEIR USE AS FGFR4 RECEPTOR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2015-07-23 WO disclosed
WO-2015108992-A1 HETEROBICYCLIC COMPOUNDS AND THEIR USE AS FGFR4 RECEPTOR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2015-07-23 WO disclosed
US-20150197519-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-07-16 US disclosed
US-20150197519-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-07-16 US disclosed
US-8093238-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-01-10 US disclosed
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-03-18 US disclosed
EP-2076512-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-07-08 EP disclosed
WO-2008044022-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253593-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 ALDH1A1 2337/4885GAA 1114/4885HSD17B10 2702/4885
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors JAK1, MTOR, MOK ALDH1A1 1714/4885GAA 1343/4885HSD17B10 2961/4885
US-10000490-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 ALDH1A1 2337/4885GAA 1114/4885HSD17B10 2702/4885
US-20150197519-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 ALDH1A1 2337/4885GAA 1114/4885HSD17B10 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.